Related Experiment Video
Updated: Jan 21, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric
David C Fajgenbaum1, Ruth-Anne Langan1, Alberto Sada Japp2
1Department of Medicine and.
Insights
Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic illness. Targeting the PI3K/Akt/mTOR pathway with sirolimus shows promise for patients refractory to IL-6 blockade, offering durable remissions.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic disorder characterized by cytokine-induced lymphoproliferation and systemic inflammation.
- Patients refractory to interleukin-6 (IL-6) blockade lack targeted therapies, necessitating the identification of novel therapeutic targets.
- The thrombocytopenia, anasarca, fever/elevated C-reactive protein, reticulin myelofibrosis, renal dysfunction, organomegaly (TAFRO) subtype of iMCD presents unique challenges.
Observation:
- Analysis of IL-6 blockade-refractory iMCD-TAFRO patients revealed increased CD8+ T cell activation.
- Elevated levels of VEGF-A and heightened activity within the PI3K/Akt/mTOR signaling pathway were observed.
- Immunohistochemistry confirmed elevated mTOR signaling via phosphorylated S6 in iMCD lymph node tissues.
Findings:
- Administration of the mTOR inhibitor, sirolimus, significantly reduced CD8+ T cell activation and decreased VEGF-A levels.
- Sirolimus treatment resulted in durable clinical responses and ongoing remissions in all three treated iMCD-TAFRO patients.
- The observed responses included remissions lasting 66, 19, and 19 months.
Implications:
- This study identifies the PI3K/Akt/mTOR signaling pathway as the first pharmacologically targetable mechanism in IL-6 blockade-refractory iMCD.
- Precision medicine targeting this pathway offers a new therapeutic strategy for iMCD patients with refractory disease.
- Prospective clinical trials evaluating sirolimus for treatment-refractory iMCD are planned, including NCT03933904.
Background:
Idiopathic multicentric Castleman disease (iMCD) is a hematologic illness involving cytokine-induced lymphoproliferation, systemic inflammation, cytopenias, and life-threatening multi-organ dysfunction. The molecular underpinnings of interleukin-6(IL-6)-blockade refractory patients remain unknown; no targeted therapies exist. In this study, we searched for therapeutic targets in IL-6-blockade refractory iMCD patients with the thrombocytopenia, anasarca, fever/elevated C-reactive protein, reticulin myelofibrosis, renal dysfunction, organomegaly (TAFRO) clinical subtype.
Methods:
We analyzed tissues and blood samples from three IL-6-blockade refractory iMCD-TAFRO patients. Cytokine panels, quantitative serum proteomics, flow cytometry of PBMCs, and pathway analyses were employed to identify novel therapeutic targets. To confirm elevated mTOR signaling, a candidate therapeutic target from the above assays, immunohistochemistry was performed for phosphorylated S6, a read-out of mTOR activation, in three iMCD lymph node tissue samples and controls. Proteomic, immunophenotypic, and clinical response assessments were performed to quantify the effects of administration of the mTOR inhibitor, sirolimus.
Results:
Studies of three IL-6-blockade refractory iMCD cases revealed increased CD8+ T cell activation, VEGF-A, and PI3K/Akt/mTOR pathway activity. Administration of sirolimus significantly attenuated CD8+ T cell activation and decreased VEGF-A levels. Sirolimus induced clinical benefit responses in all three patients with durable and ongoing remissions of 66, 19, and 19 months.
Conclusion:
This precision medicine approach identifies PI3K/Akt/mTOR signaling as the first pharmacologically-targetable pathogenic process in IL-6-blockade refractory iMCD. Prospective evaluation of sirolimus in treatment-refractory iMCD is planned (NCT03933904).
Funding:
Castleman's Awareness & Research Effort/Castleman Disease Collaborative Network, Penn Center for Precision Medicine, University Research Foundation, Intramural NIH funding, and National Heart Lung and Blood Institute.
More Related Videos
05:28A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Neuromuscular Junction And Blockade
What is Cell Signaling?
Endocrine Signaling
Paracrine Signaling